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Research Article
The antiallodynic action of pregabalin
in neuropathic pain is independent
from the opioid system
Me´lanie Kremer, MSc1,2, Ipek Yalcin, PharmD, PhD1, Laurent Nexon,
PhD1, Xavier Wurtz, MSc1,2, Rhian Alice Ceredig, PharmD, MSc1,2,
Dorothe´e Daniel, BSc1, Rachael Aredhel Hawkes, BSc1,2, Eric Salvat,
MD, PhD1,3* and Michel Barrot, PhD1*
Abstract
Background: Clinical management of neuropathic pain, which is pain arising as a consequence of a lesion or a disease
affecting the somatosensory system, partly relies on the use of anticonvulsant drugs such as gabapentinoids. Therapeutic
action of gabapentinoids such as gabapentin and pregabalin, which act by the inhibition of calcium currents through inter-
action with the a2d-1 subunit of voltage-dependent calcium channels, is well documented. However, some aspects of the
downstream mechanisms are still to be uncovered. Using behavioral, genetic, and pharmacological approaches, we tested
whether opioid receptors are necessary for the antiallodynic action of acute and/or long-term pregabalin treatment in the
specific context of neuropathic pain.
Results: Using the cuff model of neuropathic pain in mice, we show that acute pregabalin administration at high dose has a
transitory antiallodynic action, while prolonged oral pregabalin treatment leads to sustained antiallodynic action, consistent
with clinical observations. We show that pregabalin remains fully effective in -opioid receptor, in d-opioid receptor and in
k-opioid receptor deficient mice, either female or male, and its antiallodynic action is not affected by acute naloxone. Our
work also shows that long-term pregabalin treatment suppresses tumor necrosis factor-a overproduction induced by sciatic
nerve constriction in the lumbar dorsal root ganglia.
Conclusions: We demonstrate that neither acute nor long-term antiallodynic effect of pregabalin in a context of neuro-
pathic pain is mediated by the endogenous opioid system, which differs from opioid treatment of pain and antidepressant
treatment of neuropathic pain. Our data are also supportive of an impact of gabapentinoid treatment on the neuroimmune
aspect of neuropathic pain.
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Background
Neuropathic pain is deﬁned as a direct consequence of a
lesion or disease aﬀecting the somatosensory system.1
It can result from a wide range of conditions including
diabetes, nerve root compression, herpes zoster infection,
cancer, stroke, thus aﬀecting millions of persons world-
wide. This complex syndrome involves maladaptive
changes in injured sensory neurons and along the
entire nociceptive pathway within the central nervous
system.2 The recommended pharmacotherapy for neuro-
pathic pain includes the use of anticonvulsant drugs,
such as the gabapentinoids, pregabalin, and gabapentin.3
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Despite their structural similarity to the inhibitory
transmitter g-aminobutyric acid (GABA), neither gaba-
pentin nor pregabalin binds to GABAA or GABAB
receptors or interact with GABA uptake transporters.4,5
Their therapeutic eﬀect is mediated through binding to
the a2d-1 subunit of voltage-dependent calcium channels
(VDCCs).6,7 The interaction between gabapentinoids
and the a2d-1 subunit inhibits calcium currents, thus
decreasing excitatory transmitter release.5 This subunit
also plays a role in traﬃcking VDCC complexes to cell
surface8 and in synaptogenesis, and these functions are
blocked by gabapentin.9
The opioid system is involved in the action of diﬀerent
pain medications. This implication concerns on one hand
the direct analgesic action of opioids targeting the
-opioid (MOP) receptor10 and on the other hand the
indirect requirement of opioid receptors for the action
of antidepressants against neuropathic pain.11–13
During the past decade, it has been preclinically and clin-
ically proposed that gabapentinoids and opioid drugs can
have a synergistic action in neuropathic pain.14–17
However, this does not mean that gabapentinoids require
the endogenous opioid system. A potential role of the
opioid system has been recently suggested in the central,
acute, analgesic eﬀect of a high dose of pregabalin in the
tail ﬂick test in naive mice,18 and in the antinociceptive
response induced by acute gabapentin in a model of acute
inﬂammatory pain, the orofacial formalin test in mice.19
On the contrary, previous pharmacological studies
reported no eﬀect of opioid antagonists on gabapentinoid
action.20–22 For example, naloxone do not block acute
pregabalin action on abdominal constrictions in the lipo-
polysaccharide (LPS)-induced rectal hypersensitivity
model of visceral pain;21 and naloxone do not block
acute gabapentin action in the formalin test, a model of
inﬂammatory pain.22 However, these studies did not
really model the speciﬁc clinical use of gabapentinoids,
i.e. in a neuropathic pain context, and did not either
address the consequences of a long-term treatment.
Gabapentinoids have also been proposed to act on
inﬂammatory mechanisms. Gabapentin may, for exam-
ple, decrease the expression of pro-inﬂammatory cyto-
kines;16,23,24 this action has been associated with an
upregulation of the anti-inﬂammatory cytokine interleu-
kin (IL)-10.24 Interestingly, experimental evidence
supports a role of glial and/or immune cells in the patho-
physiology of neuropathic pain, particularly through the
recruitment of cytokines.25 In sustained neuropathic
pain, some pro-inﬂammatory cytokines such as tumor
necrosis factor a (TNF-a) still display enhanced expres-
sion,26–29 and blocking TNF-a has been preclinically
postulated to relieve neuropathic pain symptoms.26,30
It is, however, not known whether the expression of
TNF-a is also targeted by pregabalin in a context of
neuropathic pain.
In the present study, we used both genetic and
pharmacological approaches to evaluate whether
opioid receptors are critical for the antiallodynic action
of acute and/or long-term pregabalin treatment. We
demonstrate that neither the acute nor the long-term
antiallodynic eﬀect of pregabalin requires the endogen-
ous opioid system. We also show that long-term prega-
balin treatment inhibits the neuropathy-induced TNF-a
overproduction in dorsal root ganglia (DRG).
Methods
Animals
Experiments were performed using male C57BL/6J
mice (Charles River, L’Arbresle, France) with ages
between 8 and 10 weeks at surgery time, or with mice
lacking -opioid (MOP), d-opioid (DOP), or k-opioid
(KOP) receptors and their littermate controls. The
generation of mice lacking MOP, DOP, or KOP
receptors has been previously described.31–33 All mice
were under a C57BL/6J background for over 10 gener-
ations. Heterozygote mice were bred in our animal
facilities (breeders were kindly provided by Pr Kieﬀer
and Pr Gave´riaux-Ruﬀ), genotyping of the litters was
done, and the experiments were conducted on adult
male and female wild type and knockout littermate
mice weighing 20–30 g. We used the same number of
males and females in each experimental group. As the
wild type animals have the same background and the
same behavior, they were pooled to form the control
groups. Mice were group housed two to ﬁve per cage
and kept under a 12 hr light/dark cycle with food and
water ad libitum. A total of 104 C57BL/6J mice, 43
MOP-related, 43 DOP-related, and 43 KOP-related
transgenic mice were used for the experiments. All ani-
mals received proper care in agreement with European
guidelines (EU 2010/63). At the end of the experi-
ments, mice were killed by cervical dislocation for
immunoblot experiments, or by CO2 inhalation (CO2
Euthanasia programmer 6.5 version, TEMSEGA,
Pessac, France) followed by cervical dislocation for
other experiments, according to the institutional ethical
guidelines. The animal facilities Chronobiotron
UMS3415 are registered for animal experimentation
under the Animal House Agreement A67-2018-38. All
protocols were approved by the ‘‘Comite´ d’Ethique en
Matie`re d’Expe´rimentation Animale de Strasbourg’’
(CREMEAS, CEEA35).
Model of neuropathic pain
Neuropathic pain was induced by cuﬃng the main
branch of the right sciatic nerve.34,35 Surgeries were per-
formed under ketamine (68mg/kg)/xylazine (10mg/kg)
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intraperitoneal (i.p.) anesthesia (Centravet, Tadden,
France). The common branch of the right sciatic nerve
was exposed and a cuﬀ of PE-20 polyethylene tubing
(Harvard Apparatus, Les Ulis, France) of standardized
length (2mm) was unilaterally inserted around it (Cuﬀ
group). The shaved skin was closed using suture. Sham-
operated mice underwent the same surgical procedure
without implantation of the cuﬀ (Sham group).
Measure of mechanical allodynia
Mechanical allodynia was tested using von Frey hairs,
and results were expressed in grams. Tests were done
during the morning, starting at least 2 hr after lights
on. Mice were placed in clear Plexiglas boxes
(7 cm 9 cm 7 cm) on an elevated mesh screen.
Calibrated von Frey ﬁlaments (Bioseb, Vitrolles,
France) were applied to the plantar surface of each hind-
paw until they just bent, in a series of ascending forces up
to the mechanical threshold. Filaments were tested ﬁve
times per paw, and the paw withdrawal threshold (PWT)
was deﬁned as the lower of two consecutive ﬁlaments for
which three or more withdrawals out of the ﬁve trials
were observed.35–37 The person who conducted the
tests was blinded to the treatments.
Treatment procedures
The long-term treatment with pregabalin began two
weeks after the surgical procedure (cuﬀ implantation or
sham surgery). Pregabalin (Lyrica, Pﬁzer, Sandwich,
UK), 300, 100, 50, or 5 mg/mL, was delivered per os
through the drinking water with ad libitum access as
sole source of ﬂuid. This anticonvulsant drug was dis-
solved in water with 0.02% saccharin to increase palat-
ability, and control mice were given a solution of 0.02%
saccharin in water (vehicle solution). For acute adminis-
tration, pregabalin was dissolved in 0.9% NaCl and
administered intraperitoneally (30mg/kg, 5mL/kg).
The injection of naloxone hydrochloride (Sigma–
Aldrich, St. Quentin Fallavier, France), a competitive
non selective MOP, DOP, and KOP receptors antagonist
at high dose, was performed 25 days after surgery, i.e.
after 11 days of pregabalin treatment; or 30min after the
acute administration of pregabalin. Naloxone hydro-
chloride was dissolved in 0.9% NaCl and administered
subcutaneously (s.c., 1mg/kg, 5mL/kg). Long-term
and acute treatment experiments were conducted on
independent sets of mice.
Immunoblot analysis
In a separate experiment, DRG were collected
from Sham-vehicle, Cuﬀ-vehicle, and Cuﬀ-pregabalin
(300 mg/mL) group after two weeks of oral treatment.
Mice were killed by cervical dislocation, the back was
dissected, and a midline incision was done in the
lumbar vertebrae to extract the L4, L5, and L6 DRG
ipsilateral to the surgery. The three DRG were pooled
per animal, quickly frozen, and stored at 80C until
protein extraction.
Total proteins were extracted in 150 mL lysis buﬀer
(20mM Tris pH 7.5; 150mM NaCl; 10% glycerol; 1%
NP-40; Protease Inhibitors Cocktail, Roche), quanti-
tated with Bio-Rad Protein Assay Dye Reagent
Concentrate and stored in Laemmli buﬀer (2% sodium
dodecyl sulfate (SDS); 25% glycerol; 0.01% bromophe-
nol blue; 0.125M Tris pH 6.8); 10 mg of total protein
from individual animals was resolved by 12% SDS-poly-
acrylamide gel electrophoresis under reducing condi-
tions, and then transferred to polyvinylidene ﬂuoride
(PVDF) membrane (Immobilon, transfer membranes,
Millipore, IPVH00010). The blots were incubated
for 1 h in blocking agent (ECL kit, Amersham
Biosciences), overnight with the antibodies speciﬁc for
either TNF-a (1:500, R&D Systems, AF-410-NA) or
b-tubulin (1:50,000, Abcam, ab108342), followed
by rabbit anti-goat horseradish peroxidase (HRP)-
conjugated secondary antibodies (1:12,000, Abcam,
ab97100) or goat anti-rabbit HRP-conjugated secondary
antibodies (1:10,000, Millipore, AP307P), respectively.
Blots were revealed by chemiluminescence (ECL Prime
Western Blotting Detection Reagent, Amersham
Biosciences, RPN 2232) using Hyperﬁlm substrates
(Amersham Biosciences, RPN 1674K). Relative protein
expression was determined using the densitometry tool
of Adobe Photoshop CS5 software. The bands were eval-
uated in grayscale, subtracting the background value,
and the TNF-a/b-tubulin ratio was calculated for each
sample.
Statistical analysis
Mechanical thresholds measured with the von Frey test
provide discrete values corresponding to ﬁlaments’
values, thus limiting the relevance of classical para-
metric multi-factor analysis of variance (ANOVA). An
ANOVA-type multiple-factor nonparametric method-
ology for longitudinal data, which can take into account
both within and between factors, has recently been devel-
oped38 as a package (nparLD) for R (version 3.2.1). We
used the nparLD function to analyze the eﬀects of time,
side (left vs. right paw), sex (male vs. female), and of
treatment (e.g. surgery and/or drug dose). The asymp-
totic ANOVA-type statistic (ATS) is provided as
ATS(d.f.), with its adjusted degrees of freedom (d.f.) and
p value. Multiple comparisons between groups at a given
time point were performed with the two-sample
Wilcoxon test, with the corresponding Bonferroni
adjustment. The Wilcoxon test was also used for
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comparison of the mechanical sensitivity thresholds
between males and females. Immunoblotting experi-
ments were analyzed with the nonparametric Kruskal–
Wallis test, followed by multiple comparisons with the
Wilcoxon test. The signiﬁcance level was set at p< 0.05.
Data were represented as mean SEM.
Results
Antiallodynic action of chronic oral
pregabalin: Dose response
The mechanical sensitivity of the C57BL/6J mice was
assessed using von Frey hairs. Although sham surgery
did not inﬂuence mechanical thresholds (Figure 1(a)
and (b)), cuﬀ implantation induced an ipsilateral mech-
anical allodynia (Figure 1(a); surgery time interaction,
ATS(2.9)¼ 3.9, p< 0.005 on postsurgery days 1–19). We
did not observe any change in the nociceptive threshold
of the left paw, contralateral to the cuﬀ implantation; 19
days after surgery, we started treatment with diﬀerent
doses of pregabalin (300, 100, 50, or 5 mg/mL) or with
vehicle solution (0.02% saccharin). Pregabalin treatment
at doses 100 and 300 mg/mL alleviated the cuﬀ-
induced allodynia after about three days of treatment
(Figure 1(a); group time interaction, ATS(13.9)¼ 2.8,
p< 0.001; multiple comparisons: ‘‘Cuﬀ Vehicle’’
< ‘‘Cuﬀ Pregabalin 100 mg/mL and Pregabalin
300 mg/mL’’ at p< 0.05 on postsurgery days 22–40).
A partial antiallodynic eﬀect was also present with
the 50 mg/mL dose of pregabalin after eight days
of treatment (Figure 1(a); multiple comparisons:
‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ Pregabalin 50 mg/mL’’< ‘‘Sham
Vehicle’’ at p< 0.05 on postsurgery days 27–40).
Treatments at diﬀerent doses did not aﬀect the contra-
lateral nociceptive thresholds (Figure 1(a)). The 5 mg/mL
dose of pregabalin had no signiﬁcant eﬀect (Figure 1(a)).
Chronic oral treatment with pregabalin at 300 mg/mL
suppressed cuﬀ-induced allodynia (Figure 1(a)), but it
did not aﬀect mechanical thresholds of mice of the
Sham group (Figure 1(b)).
The drinking bottles were regularly weighed during
the experiment. Considering the volume of solution
drank by the mice per 24 h, the 5 mg/mL solution was
equivalent to 0.78 0.05mg/kg/day, the 50 mg/mL solu-
tion was equivalent to 8.09 0.38mg/kg/day, the 100 mg/
mL solution was equivalent to 15.64 0.65mg/kg/day,
and the 300mg/mL solution was equivalent to 44.63
1.39mg/kg/day (Figure 1(c)). These amounts were in
fact mostly taken over the 12 h night period, period
during which mice usually drink.
Body weights of mice treated chronically with diﬀer-
ent doses of pregabalin or vehicle were also assessed
throughout the experiment. Cuﬀ animals showed a dif-
ference in weight gain in the days following the surgery
compared to Sham animals. This diﬀerence persisted in
Cuﬀ mice treated with vehicle or pregabalin at doses of 5
and 50 mg/mL. Pregabalin treatment at doses of 100 and
300 mg/mL, which relieved neuropathic allodynia,
reversed this deﬁcit in weight gain (Figure 1(d); group-
 time interaction, ATS(11.2)¼ 6.2, p< 0.001; multiple
comparisons: ‘‘Cuﬀ Vehicle, Pregabalin 5 mg/mL and
Pregabalin 50 mg/mL’’< ‘‘Sham Vehicle’’ at p< 0.05 on
postsurgery days 7–40, ‘‘Cuﬀ Pregabalin 100 mg/mL and
Pregabalin 300 mg/mL’’< ‘‘Sham Vehicle’’ at p< 0.01 on
postsurgery days 7–19 and ‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ
Pregabalin 100 mg/mL and Pregabalin 300 mg/mL’’ at
p< 0.01 on postsurgery days 25–40).
Response to pregabalin: Male/female
comparison in wild-type mice
Mechanical sensitivity thresholds of female mice were
signiﬁcantly lower than in males (baseline threshold
values of paws are equal to 4.67 g 0.19 for males and
3.28 g 0.13 for females, male vs. female: W¼ 79.5,
p< 0.001). Both male and female mice developed mech-
anical allodynia after cuﬀ implantation and pregabalin
treatment suppressed the cuﬀ-induced allodynia in both
sexes (Figure 2(a); Male mice: group time interaction,
ATS(6.1)¼ 7.5, p< 0.001; multiple comparisons: ‘‘Cuﬀ
Vehicle’’< ‘‘Sham Vehicle’’ at p< 0.05 on treatment
days 0–12 and ‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ Pregabalin
300 mg/mL’’ at p< 0.05 on treatment days 9–12;
Female mice: group time interaction, ATS(5.9)¼ 5.1,
p< 0.001; multiple comparisons: ‘‘Cuﬀ Vehicle’’<
‘‘Sham Vehicle’’ at p< 0.05 on treatment days 0–12
and ‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ Pregabalin 300 mg/mL’’ at
p< 0.05 on treatment days 9–12).
Chronic oral pregabalin treatment
in opioid receptor deficient mice
The MOP, DOP, or KOP receptors-deﬁcient mice dis-
played baselines for mechanical sensitivity that were
similar to the wild-type littermates (Figure 2(b)). We
controlled in our facilities that morphine has no more
action in MOP-deﬁcient mice.36 Two weeks after sur-
gery, we started the oral treatment with either pregabalin
(300 mg/mL) or vehicle (0.02% saccharin) solutions.
Pregabalin treatment alleviated cuﬀ-induced allodynia
in wild-type mice (Figure 2(b); group time interaction,
ATS(6.9)¼ 13.1, p< 0.001; multiple comparisons: ‘‘Cuﬀ
Vehicle’’< ‘‘Cuﬀ Pregabalin’’ at p< 0.05 on treatment
days 9–12). The same antiallodynic eﬀect was also pre-
sent in MOP receptors (Figure 2(c); group time inter-
action, ATS(5.2)¼ 10.4, p< 0.001; multiple comparisons:
‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ Pregabalin’’ at p< 0.05 on
treatment days 9–12), DOP receptors (Figure 2(c);
group time interaction, ATS(7.1)¼ 8.8, p< 0.001;
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multiple comparisons: ‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ
Pregabalin’’ at p< 0.05 on treatment days 9–12), and
KOP receptors-deﬁcient mice (Figure 2(c); group time
interaction, ATS(5.5)¼ 8.4, p< 0.001; multiple
comparisons: ‘‘Cuﬀ Vehicle’’< ‘‘Cuﬀ Pregabalin’’ at
p< 0.05 on treatment days 9–12). Thus, pregabalin sup-
pressed cuﬀ-induced allodynia independently of the pres-
ence or no of the opioid receptors.
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Figure 1. Chronic pregabalin treatment. (a) Two weeks after unilateral cuff insertion around the right sciatic nerve, chronic oral
treatment with pregabalin started and lasted three weeks. The animals (n¼ 5 per each group) freely drink pregabalin (5, 50, 100, or
300 mg/mL) with 0.02% saccharin, or vehicle composed of 0.02% saccharin in water, as sole source of fluid. Mechanical PWTwere evaluated
at indicated time points using von Frey filaments. Vehicle treatment did not affect mechanical sensitivity of either Sham or Cuff mice.
Pregabalin treatment was ineffective at dose 5 mg/mL, partially effective at dose 50mg/mL, and reversed the cuff-induced allodynia at doses
100 and 300 mg/mL. (b) Pregabalin treatment at dose 300 mg/mL had no effect per se on sham-operated mice. (c) Histogram showing the
equivalence between mg/mL and mg/kg/day of the different doses. (d) Time course of changes in the body weight of the animals throughout
the experiment. Data are expressed as mean SEM.
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Naloxone effect on long lasting pregabalin treatment
We tested the consequence of an acute injection of the
opioid receptor antagonist naloxone (1mg/kg, s.c.) on
the antiallodynic action of pregabalin in C57BL/6
J male mice. After 10 days of oral treatment with prega-
balin or vehicle (Figure 3(a); group time interaction,
ATS(11.1)¼ 9.3, p< 0.001; multiple comparisons: ‘‘Cuﬀ
Vehicle’’< ‘‘Cuﬀ Pregabalin’’ at p< 0.005 on postsur-
gery days 19 to 24 and ‘‘Cuﬀ Pregabalin’’¼ (‘‘Sham
Pregabalin’’ or ‘‘Sham Vehicle’’) at p¼ 1.0 on postsur-
gery days 22 and 24), acute injection of naloxone did not
suppress the antiallodynic eﬀect of chronic pregabalin
treatment (Figure 3(c)). We also observed that naloxone
per se had no eﬀect in mice with Sham surgery or in mice
that received vehicle alone (Figure 3(b)).
Transitory relief of neuropathic allodynia
by acute pregabalin
In wild-type mice, an acute injection of pregabalin at a
high dose (30mg/kg, i.p.) had a transitory antiallodynic
eﬀect in Cuﬀ mice, without aﬀecting Sham animals
(Figure 4; group time interaction, ATS(2.7)¼ 12.3,
p< 0.001; multiple comparisons: ‘‘Cuﬀ Pregabalin’’¼
‘‘Sham Pregabalin’’ at p> 0.7 on post-administration
time 60min and ‘‘Cuﬀ Pregabalin’’< ‘‘Sham
Pregabalin’’ at p< 0.001 on post-administration time
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Figure 2. Effect of chronic oral pregabalin in opioid receptor deficient mice. Pregabalin treatment (300 mg/mL i.e 44.63 mg/kg/day in the
drinking water, with 0.02% saccharin) or control treatment (0.02% saccharin) started two weeks following surgery and lasted 12 days.
Mechanical allodynia was tested using von Frey hairs. (a) The mechanical sensitivity threshold (PWT) of female mice is lower than that of
male mice. However, both sexes developed mechanical allodynia similarly and pregabalin was effective in reversing the cuff-induced
allodynia in both male and female mice. Males and females were then pooled in each experimental group. (b) Chronic pregabalin treatment
abolishes the ipsilateral cuff-induced allodynia in wild type mice, as well as in MOP, DOP, or KOP receptors-deficient mice (c). (Data are
pooled from three independents experiments, each final group includes the same number of male and female mice, *p< 0.05 as compared
with Sham-operated control group drinking vehicle). Data are expressed as mean SEM.
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0, 30, and 120min). The same transitory eﬀect was also
present in MOP receptors (Figure 4; group time inter-
action, ATS(1,.6)¼ 11.1, p< 0.001; multiple comparisons:
‘‘Cuﬀ Pregabalin’’¼ ‘‘Sham Pregabalin’’ at p¼ 1.0 on
post-administration time 60min and ‘‘Cuﬀ Pregabalin’’
< ‘‘Sham Pregabalin’’ at p< 0.01 on post-administration
time 0, 30, and 120min), DOP receptors (Figure 4;
group time interaction, ATS(2.2)¼ 12.7, p< 0.001;
multiple comparisons: ‘‘Cuﬀ Pregabalin’’¼ ‘‘Sham
Pregabalin’’ at p> 0.7 on post-administration time
60min and ‘‘Cuﬀ Pregabalin’’< ‘‘Sham Pregabalin’’ at
p< 0.01 on post-administration time 0, 30, and 120min),
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Figure 3. Acute opioid receptor antagonist in chronic pregabalin treatment. (a) Two weeks after unilateral cuff insertion, the oral
treatment with pregabalin, or vehicle control started. Mechanical threshold of hindpaw withdrawal (PWT) was evaluated using von Frey
filaments. Pregabalin treatment suppressed the cuff-induced alloynia. (b, c) After at least 10 days of pregabalin (300 mg/mL i.e 44.63 mg/kg/
day, 0.02% saccharin) or vehicle treatment, the animals received an injection of the opioid receptor antagonist naloxone (1 mg/kg, s.c.) or
the control saline solution. Mechanical threshold for hindpaw withdrawal was measured before 30 and 120 minutes after injection. No
effect of naloxone or saline was seen in Sham mice or in pregabalin-treated neuropathic animals (n¼ 9–10, *p< 0.005 compared to the
Sham-operated control group). Data are expressed as mean SEM.
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Figure 4. Effect of acute pregabalin in opioid receptor-deficient mice. Two weeks after cuff implantation, the animals received an acute
injection of saline (i.p.) or of pregabalin (30 mg/kg, i.p.). Nociceptive mechanical threshold (PWT) was tested before (0 min) 30, 60, and
120 min after these acute injections. Acute pregabalin had a transitory antiallodynic effect in wild type Cuff mice without affecting Sham
animals. Similar results were obtained in MOP, DOP, and KOP receptors-deficient mice. (Number of animals are given between brackets,
data are pooled from three independent experiments, each final group includes the same number of male and female mice, *p< 0.005
compared to Sham-operated controls receiving pregabalin.) Data are expressed as mean SEM.
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and KOP receptors-deﬁcient mice (Figure 4; group-
 time interaction, ATS(2.3)¼ 10.5, p< 0.001; multiple
comparisons: ‘‘Cuﬀ Pregabalin’’¼ ‘‘Sham Pregabalin’’
at p> 0.6 on post-administration time 60min and
‘‘Cuﬀ Pregabalin’’< ‘‘Sham Pregabalin’’ at p< 0.01
on post-administration time 0, 30, and 120min). These
transitory antiallodynic eﬀects disappeared 120min after
injection of pregabalin.
Naloxone effect on acute pregabalin treatment
Naloxone (1mg/kg) did not suppress the transitory anti-
allodynic action of acute pregabalin administration
(Figure 5(a); group interaction, ATS(1.0)¼ 181.7,
p< 0.001; multiple comparisons: ‘‘Cuﬀ Saline’’< ‘‘Sham
Saline’’ at p< 0.001 for acute saline administration and at
p< 0.005 for acute naloxone administration) (Figure 5(b),
acute saline; group time interaction, ATS(1.0)¼ 12.7,
p< 0.001; multiple comparisons: ‘‘Cuﬀ Pregabalin’’
< ‘‘Sham Pregabalin’’ at p< 0.001 preinjection and
‘‘Cuﬀ Pregabalin’’¼ ‘‘Sham Pregabalin’’ at p> 0.5 post-
injection; Acute Naloxone; group time interaction,
ATS(1.0)¼ 13.7, p< 0.001; multiple comparisons: ‘‘Cuﬀ
Pregabalin’’< ‘‘Sham Pregabalin’’ at p< 0.001 preinjec-
tion and ‘‘Cuﬀ Pregabalin’’¼ ‘‘Sham Pregabalin’’ at
p> 0.8 postinjection).
Long-term pregabalin has an anti-TNF- action
Using Western blot, we observed increased levels of the
membrane-bound form of TNF-a (mTNF-a) in the
lumbar DRG of C57BL/6J Cuﬀ mice at four weeks post-
injury. The long-term treatment with pregabalin reversed
this increase in mTNF-a. (Figure 6; H(2.0)¼ 16.2,
p< 0.001; multiple comparisons: ‘‘Cuﬀ
Vehicle’’> (‘‘Cuﬀ Pregabalin’’ or ‘‘Sham Vehicle’’) at
p< 0.005).
Discussion
In the present work, we studied the role of opioid recep-
tors in both the long-term and the acute transitory anti-
allodynic action of systemic pregabalin in a model of
neuropathic pain. In both cases, we show that the
endogenous opioid system is not necessary for this
action. We also show that a long-term pregabalin treat-
ment suppresses the DRG TNF-a overexpression that
accompanies neuropathic pain.
Clinically, ﬁrst line pharmacological treatments to
relieve neuropathic pain include anticonvulsants and
antidepressants. Gabapentinoid anticonvulsants, which
target the VDCCs a2d-1 subunit, have proved to be
eﬀective in a number of neuropathic pain conditions.3,39
Similarly to many reports in various animal
models,6,20,40,41 we showed that pregabalin has a short-
term transitory antiallodynic action after an acute
administration; however, this eﬀect cannot be considered
as representative of the main clinical therapeutic eﬀect
since the mechanical allodynia reappears within 2 h fol-
lowing the injection. Interestingly, the beneﬁt of prega-
balin treatment is sustained after three days of oral
administration, which is in agreement with other results
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Figure 5. Acute opioid receptor antagonist in acute pregabalin treatment. Two weeks after unilateral cuff surgery, mice received an
injection of pregabalin (30 mg/kg, i.p.) or saline control; 30 min later, they received an injection of the opioid receptor antagonist naloxone
(1 mg/kg, s.c.) or control saline solution. Mechanical threshold for the right hindpaw (PWT) was measured before the first injection and
30 min after the second injection. (a) Naloxone and saline had no effect in Sham mice and in Cuff mice that received control treatment
(n¼ 7–8, *p< 0.005 compared to the Sham-operated control group). (b) Naloxone and saline had no effect in Sham mice and in Cuff mice
that received pregabalin treatment (30 mg/kg, i.p.) (n¼ 7–8, *p< 0.005 compared to the Sham-operated control group). Data are
expressed as mean SEM.
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obtained with systemic delivery of another gabapenti-
noid, gabapentin,20,42 or in other neuropathic pain
models.24,43 This sustained action may more likely be
representative of the clinical use and action of gabapen-
tinoids in neuropathic pain.44,45
Critical aspects of mechanism(s) by which gabapenti-
noids alleviate neuropathic pain is (are) now well
described. Gabapentinoids inhibit calcium currents
through direct interaction with the a2d-1 subunit, thus
decreasing excitatory transmitter release and spinal sen-
sitization.8,46 This target subunit is upregulated in the
dorsal horn of the spinal cord and in DRG neurons in
several models of neuropathic pain and this increase
in a2d-1 correlates with the onset of allodynia.47
Furthermore, experiments performed in transgenic mice
overexpressing the a2d-1 subunit showed enhanced cal-
cium currents recorded in DRG neurons, as well as noci-
ceptive behavior characterized by hyperalgesia in the
absence of nerve damage.48 In contrast, a2d-1 deﬁcient
mice display reduced DRG calcium currents, have lower
baseline mechanical sensitivity, and show delayed mech-
anical hypersensitivity after partial sciatic nerve liga-
tion.49 In DRG neurons, a2d-1 upregulation recruits
mitochondrial Ca2þ to prolong intracellular Ca2þ signals
evoked by depolarization.50 This mechanism may con-
tribute to the aberrant neurotransmission observed in
neuropathic pain. Pregabalin antiallodynic eﬀect is asso-
ciated with decreased traﬃcking of the a2d-1 subunit to
presynaptic terminals of DRG neurons;8,46 and within
the dorsal horn, gabapentinoids also decrease the amp-
litude of excitatory postsynaptic currents.51
In addition to these actions, two studies suggested
that gabapentinoids may also recruit the endogenous
opioid system,18,19 which is well known for playing
a crucial role in the control of nociception and
pain.10,11,52 Indeed, the opioid antagonist naloxone
reversed the acute antinociceptive activity of a high
dose of pregabalin in naive mice.18 Another study also
showed an eﬀect of naltrexone on the acute action of
gabapentin in a model of orofacial inﬂammatory
pain.19 These recent data diﬀer from previous studies
on gabapentinoid drugs, which mostly reported nalox-
one to be ineﬀective in blocking gabapentinoid-induced
analgesia in diﬀerent pain models.20–22 However, most of
these studies were not done in models of neuropathic
pain, which is the clinical pain condition for which gaba-
pentinoids have legal authorization for prescription in
various countries. Beside pharmacological approach,
the present study used genetic deletion of opioid recep-
tors for the ﬁrst time, which further clariﬁes the involve-
ment of the opioid system in both acute and chronic
antiallodynic action of pregabalin in neuropathic pain.
We demonstrate that neither acute nor long-term anti-
allodynic eﬀect of pregabalin requires the presence of
opioid receptors. Both our results and previous stu-
dies20–22 refute the involvement of the opioid system in
the antiallodynic action of pregabalin in neuropathic
pain, which does not exclude a possible involvement of
these receptors in gabapentinoid action on other types of
pain.
The opioid system via MOP, DOP, and KOP recep-
tors plays a crucial role in the inhibitory controls of
pain10,52,53 and also participates in the therapeutic
action of various pain killers. Thus, MOP receptors are
the primary molecular target for the analgesic action of
opioids such as morphine, codeine, fentanyl, or trama-
dol.10,54,55 Indirectly, the opioid system is also necessary
for the antiallodynic action of tricyclic antidepressant
drugs, which requires DOP receptors, but not MOP or
KOP receptors.11,36,56 Our results strengthen the idea
that antidepressant and anticonvulsant treatments allevi-
ate neuropathic pain through independent mechanisms.
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Figure 6. Long-term pregabalin displays an anti-TNF-a action on lumbar dorsal root ganglia of neuropathic mice. (a) Representative
picture of Western blot illustrating the increased TNF-a levels in DRG of Cuff mice four to five weeks after induction of the neuropathy,
and the anti-TNF-a action of the long-term pregabalin treatment (300 mg/mL i.e. 44.63 mg/kg/day). (b) Histogram presenting the Western
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These mechanistic diﬀerences may be in favor of com-
bination pharmacotherapy for the management of
neuropathic pain using both gabapentinoids and anti-
depressants,57,58 although the beneﬁt of such a com-
bination is still controversial,3,59 or using both
gabapentinoids and opioid drugs.14–17
In the last decade, there has been an increasing
number of studies which now provide compelling evi-
dence that neuropathic pain pathogenesis is not simply
conﬁned to changes in the activity of neuronal systems,
but that it also involves interactions between neurons,
immune cells, and glial cells, including the involvement
of inﬂammatory cytokines and chemokines.25,60 Indeed,
peripheral nerve injury recruits the immune system at
various anatomical locations, including the lesion site,
DRG, spinal cord, and supraspinal sites associated
with pain pathways.25 Pro-inﬂammatory cytokines pro-
duced after nerve injury could participate to the initi-
ation and maintenance of neuropathic pain. Among
these cytokines, TNF-a has the ability to also favor pro-
duction of other cytokines.28 The direct anti-TNF-a
drugs inﬂiximab and etanercept are clinically used to
treat autoimmune diseases,61 and these drugs have been
shown to have some action on neuropathic pain symp-
toms both in animal models and in humans.26,30,62–64
In particular, inﬂiximab and etanercept can relieve
neuropathic allodynia in the model of neuropathic pain
used for the present study.26 Our results show that preg-
abalin can display an indirect anti-TNF-a action, as seen
on DRG from mice with neuropathic pain. This result is
in agreement with previous reports on gabapentin sug-
gesting an indirect action of this drug on cytokines.16,24
Thus, it has been proposed that gabapentin could upre-
gulate the expression of the anti-inﬂammatory cytokine
IL-10 in the spinal cord, leading to the inhibition of the
expression of pro-inﬂammatory cytokines, TNF-a, but
also IL-1b and IL-6.16,24
Conclusions
This study demonstrates that none of the three opioid
receptors is necessary for the antiallodynic action of
acute or chronic pregabalin in a neuropathic pain
context. Moreover, long-term pregabalin treatment
decreases TNF-a in DRG. Further studies will be
needed to elucidate the mechanism by which the direct
action of pregabalin on the neuronal VDCCs a2d-1 sub-
unit may downregulate DRG TNF-a expression, which
is mostly produced by non-neuronal cells. While the
direct action of pregabalin on its target provides an
explanation for acute pregabalin action at high dose,
the sustained eﬀect of prolonged treatment suggests the
involvement of other downstream mechanisms the eluci-
dation of which may provide new candidates for
pharmacological targeting.
Acknowledgments
The authors thank Dr Jean-Luc Rodeau for his help concern-
ing statistical tests, and Ste´phane Doridot for animal care and
genotyping. They are grateful to Pr Brigitte Kieﬀer (McGill
University, Canada) and Pr Claire Gave´riaux-Ruﬀ (IGBMC,
France) for providing MOP, DOP, and KOP receptors-
deﬁcient mouse breeders.
Authors Contributions
ES and MB equally participated to this work. MK and IY did
all surgeries. RAH and RAC performed dose responses. MK,
LN, and XW performed behavioral tests on chronically treated
opioid-receptor deﬁcient mice. MK performed behavioral tests
concerning naloxone and acute pregabalin. MK and DD per-
formed the Western blot experiment. MB, MK, IY, and ES
codesigned and supervised all experiments. MK collected and
analyzed all data. MK and MB drafted the article. All authors
revised the article prior to submission.
Declaration of Conflicting Interests
The author(s) declared no potential conﬂicts of interest with
respect to the research, authorship, and/or publication of this
article: The authors declare that they have no competing
interests.
Funding
The author(s) disclosed receipt of the following ﬁnancial sup-
port for the research, authorship, and/or publication of this
article: This work was supported by the Centre National de
la Recherche Scientiﬁque (CNRS, contract UPR3212) and
the Universite´ de Strasbourg (UPR3212), by a CNRS disability
PhD fellowship (to MK), by Fondation d’Entreprise Banque
Populaire (to MK), and by Fe´de´eh-Hewlett-Packard (to MK).
References
1. Jensen TS, Baron R, Haanpaa M, et al. A new definition of
neuropathic pain. Pain 2011; 152: 2204–2205.
2. von Hehn CA, Baron R and Woolf CJ. Deconstructing the
neuropathic pain phenotype to reveal neural mechanisms.
Neuron 2012; 73: 638–652.
3. Finnerup NB, Attal N, Haroutounian S, et al.
Pharmacotherapy for neuropathic pain in adults: a system-
atic review and meta-analysis. Lancet Neurol 2015; 14:
162–173.
4. Lanneau C, Green A, Hirst WD, et al. Gabapentin is not a
GABAB receptor agonist. Neuropharmacology 2001; 41:
965–975.
5. Mico JA and Prieto R. Elucidating the mechanism of action
of pregabalin: alpha(2)delta as a therapeutic target in anx-
iety. CNS Drugs 2012; 26: 637–648.
6. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-
delta-1 subunit of voltage-dependent calcium channels as a
molecular target for pain mediating the analgesic actions
of pregabalin. Proc Natl Acad Sci USA 2006; 103:
17537–17542.
7. Gee NS, Brown JP, Dissanayake VU, et al. The novel anti-
convulsant drug, gabapentin (Neurontin), binds to the
10 Molecular Pain 0(0)
alpha2delta subunit of a calcium channel. J Biol Chem
1996; 271: 5768–5776.
8. Bauer CS, Nieto-Rostro M, Rahman W, et al. The
increased trafficking of the calcium channel subunit
alpha2delta-1 to presynaptic terminals in neuropathic
pain is inhibited by the alpha2delta ligand pregabalin.
J Neurosci 2009; 29: 4076–4088.
9. Eroglu C, Allen NJ, Susman MW, et al. The gabapentin
receptor alpha2delta-1 is the neuronal thrombospondin
receptor responsible for excitatory CNS synaptogenesis.
Cell 2009; 139: 380–392.
10. Gaveriaux-Ruff C and Kieffer BL. Opioid receptor genes
inactivated in mice: the highlights. Neuropeptides 2002; 36:
62–71.
11. Benbouzid M, Gaveriaux-Ruff C, Yalcin I, et al. Delta-
opioid receptors are critical for tricyclic antidepressant
treatment of neuropathic allodynia. Biol Psychiatry 2008;
63: 633–636.
12. Mico JA, Ardid D, Berrocoso E, et al. Antidepressants and
pain. Trends Pharmacol Sci 2006; 27: 348–354.
13. Marchand F, Ardid D, Chapuy E, et al. Evidence for an
involvement of supraspinal delta- and spinal mu-opioid
receptors in the antihyperalgesic effect of chronically
administered clomipramine in mononeuropathic rats.
J Pharmacol Exp Ther 2003; 307: 268–274.
14. Dou Z, Jiang Z and Zhong J. Efficacy and safety of preg-
abalin in patients with neuropathic cancer pain undergoing
morphine therapy. Asia Pac J Clin Oncol 2014; 10:
12311–12319.
15. Chaparro LE, Wiffen PJ, Moore RA, et al. Combination
pharmacotherapy for the treatment of neuropathic pain in
adults. Cochrane Database Syst Rev 2012; 7: CD008943.
16. Bao YH, Zhou QH, Chen R, et al. Gabapentin enhances
the morphine anti-nociceptive effect in neuropathic pain
via the interleukin-10-heme oxygenase-1 signalling path-
way in rats. J Mol Neurosci 2014; 54: 137–146.
17. De la OAM, Diaz-Reval MI, Cortes-Arroyo AR, et al.
Anti-nociceptive synergism of morphine and gabapentin
in neuropathic pain induced by chronic constriction
injury. Pharmacol Biochem Behav 2009; 92: 457–464.
18. Kaygisiz B, Kilic FS, Senguleroglu N, et al. The antinoci-
ceptive effect and mechanisms of action of pregabalin in
mice. Pharmacol Rep 2015; 67: 129–133.
19. Miranda HF, Sierralta F, Lux S, et al. Involvement of
nitridergic and opioidergic pathways in the antinociception
of gabapentin in the orofacial formalin test in mice.
Pharmacol Rep 2015; 67: 399–403.
20. Benbouzid M, Choucair-Jaafar N, Yalcin I, et al. Chronic,
but not acute, tricyclic antidepressant treatment alleviates
neuropathic allodynia after sciatic nerve cuffing in mice.
Eur J Pain 2008; 12: 1008–1017.
21. Eutamene H, Coelho AM, Theodorou V, et al.
Antinociceptive effect of pregabalin in septic shock-
induced rectal hypersensitivity in rats. J Pharmacol Exp
Ther 2000; 295: 162–167.
22. Field MJ, Oles RJ, Lewis AS, et al. Gabapentin (neu-
rontin) and S-(þ)-3-isobutylgaba represent a novel class
of selective antihyperalgesic agents. Br J Pharmacol 1997;
121: 1513–1522.
23. Dias JM, de, Brito TV, de Aguiar Magalhaes D, et al.
Gabapentin, a synthetic analogue of gamma aminobutyric
acid, reverses systemic acute inflammation and oxidative
stress in mice. Inflammation 2014; 37: 1826–1836.
24. Lee BS, Jun IG, Kim SH, et al. Intrathecal gabapentin
increases interleukin-10 expression and inhibits pro-
inflammatory cytokine in a rat model of neuropathic
pain. J Korean Med Sci 2013; 28: 308–314.
25. Austin PJ and Moalem-Taylor G. The neuro-immune bal-
ance in neuropathic pain: involvement of inflammatory
immune cells, immune-like glial cells and cytokines.
J Neuroimmunol 2010; 229: 26–50.
26. Bohren Y, Tessier LH, Megat S, et al. Antidepressants
suppress neuropathic pain by a peripheral beta2-adreno-
ceptor mediated anti-TNFalpha mechanism. Neurobiol
Dis 2013; 60: 39–50.
27. Uceyler N, Rogausch JP, Toyka KV, et al. Differential
expression of cytokines in painful and painless neuropa-
thies. Neurology 2007; 69: 42–49.
28. Leung L and Cahill CM. TNF-alpha and neuropathic pain
– a review. J Neuroinflammation 2010; 7: 27.
29. Empl M, Renaud S, Erne B, et al. TNF-alpha expression in
painful and nonpainful neuropathies. Neurology 2001; 56:
1371–1377.
30. Sommer C, Lindenlaub T, Teuteberg P, et al. Anti-
TNF-neutralizing antibodies reduce pain-related behavior
in two different mouse models of painful mononeuropathy.
Brain Res 2001; 913: 86–89.
31. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for
delta- and mu-opioid receptors exhibit opposing alter-
ations of emotional responses. Nat Genet 2000; 25:
195–200.
32. Matthes HW, Maldonado R, Simonin F, et al. Loss of
morphine-induced analgesia, reward effect and withdrawal
symptoms in mice lacking the mu-opioid-receptor gene.
Nature 1996; 383: 819–823.
33. Simonin F, Valverde O, Smadja C, et al. Disruption of the
kappa-opioid receptor gene in mice enhances sensitivity to
chemical visceral pain, impairs pharmacological actions of
the selective kappa-agonist U-50,488H and attenuates
morphine withdrawal. EMBO J 1998; 17: 886–897.
34. Benbouzid M, Pallage V, Rajalu M, et al. Sciatic nerve
cuffing in mice: a model of sustained neuropathic pain.
Eur J Pain 2008; 12: 591–599.
35. Yalcin I, Megat S, Barthas F, et al. The sciatic nerve cuff-
ing model of neuropathic pain in mice. J Vis Exp 2014; 89:
51608.
36. Bohren Y, Karavelic D, Tessier LH, et al. Mu-opioid
receptors are not necessary for nortriptyline treatment of
neuropathic allodynia. Eur J Pain 2010; 14: 700–704.
37. Barrot M. Tests and models of nociception and pain in
rodents. Neuroscience 2012; 211: 39–50.
38. Noguchi K, Gel YR, Brunner E, et al. nparLD: an R soft-
ware package for the nonparametric analysis of longitu-
dinal data in factorial experiments. J Stat Softw 2012; 50:
1–23.
39. Gilron I. Gabapentin and pregabalin for chronic neuro-
pathic and early postsurgical pain: current evidence
and future directions. Curr Opin Anaesthesiol 2007; 20:
456–472.
Kremer et al. 11
40. Wallin J, Cui JG, Yakhnitsa V, et al. Gabapentin and
pregabalin suppress tactile allodynia and potentiate
spinal cord stimulation in a model of neuropathy. Eur J
Pain 2002; 6: 261–272.
41. Field MJ, McCleary S, Hughes J, et al. Gabapentin and
pregabalin, but not morphine and amitriptyline, block
both static and dynamic components of mechanical allo-
dynia induced by streptozocin in the rat. Pain 1999; 80:
391–398.
42. Yalcin I, Tessier LH, Petit-Demouliere N, et al. Beta2-
adrenoceptors are essential for desipramine, venlafaxine
or reboxetine action in neuropathic pain. Neurobiol Dis
2009; 33: 386–394.
43. Coderre TJ, Kumar N, Lefebvre CD, et al. Evidence that
gabapentin reduces neuropathic pain by inhibiting the
spinal release of glutamate. J Neurochem 2005; 94:
1131–1139.
44. Cheshire WP. Defining the role for gabapentin in the treat-
ment of trigeminal neuralgia: a retrospective study. J Pain
2002; 3: 137–142.
45. Sharma U, Griesing T, Emir B, et al. Time to onset of
neuropathic pain reduction: A retrospective analysis of
data from nine controlled trials of pregabalin for painful
diabetic peripheral neuropathy and postherpetic neuralgia.
Am J Ther 2010; 17: 577–585.
46. Hendrich J, Bauer CS and Dolphin AC. Chronic pregaba-
lin inhibits synaptic transmission between rat dorsal root
ganglion and dorsal horn neurons in culture. Channels
(Austin) 2012; 6: 124–132.
47. Bauer CS, Rahman W, Tran-van-Minh A, et al. The anti-
allodynic alpha(2)delta ligand pregabalin inhibits the traf-
ficking of the calcium channel alpha(2)delta-1 subunit to
presynaptic terminals in vivo. Biochem Soc Trans 2010; 38:
525–528.
48. Li CY, Zhang XL, Matthews EA, et al. Calcium channel
alpha2delta1 subunit mediates spinal hyperexcitability in
pain modulation. Pain 2006; 125: 20–34.
49. Patel R, Bauer CS, Nieto-Rostro M, et al. alpha2delta-1
gene deletion affects somatosensory neuron function and
delays mechanical hypersensitivity in response to periph-
eral nerve damage. J Neurosci 2013; 33: 16412–16426.
50. D’Arco M, Margas W, Cassidy JS, et al. The upregulation
of alpha2delta-1 subunit modulates activity-dependent
Ca2þ signals in sensory neurons. J Neurosci 2015; 35:
5891–5903.
51. Biggs JE, Boakye PA, Ganesan N, et al. Analysis of the
long-term actions of gabapentin and pregabalin in dorsal
root ganglia and substantia gelatinosa. J Neurophysiol
2014; 112: 2398–2412.
52. Dierich A and Kieffer BL. Knockout mouse models in pain
research. Methods Mol Med 2004; 99: 269–299.
53. Mogil JS, Yu L and Basbaum AI. Pain genes?: natural
variation and transgenic mutants. Annu Rev Neurosci
2000; 23: 777–811.
54. Gibson TP. Pharmacokinetics, efficacy, and safety of anal-
gesia with a focus on tramadol HCl. Am J Med 1996; 101:
47S–53S.
55. Pasternak GW and Pan YX. Mu opioids and their recep-
tors: evolution of a concept. Pharmacol Rev 2013; 65:
1257–1317.
56. Megat S, Bohren Y, Doridot S, et al. kappa-Opioid recep-
tors are not necessary for the antidepressant treatment of
neuropathic pain. Br J Pharmacol 2015; 172: 1034–1044.
57. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gaba-
pentin, alone and in combination for neuropathic pain: a
double-blind, randomised controlled crossover trial.
Lancet 2009; 374: 1252–1261.
58. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and preg-
abalin: high-dose monotherapy or their combination? The
‘‘COMBO-DN study’’ – a multinational, randomized,
double-blind, parallel-group study in patients with diabetic
peripheral neuropathic pain. Pain 2013; 154: 2616–2625.
59. Gilron I, Jensen TS and Dickenson AH. Combination
pharmacotherapy for management of chronic pain: from
bench to bedside. Lancet Neurol 2013; 12: 1084–1095.
60. Vallejo R, Tilley DM, Vogel L, et al. The role of glia and
the immune system in the development and maintenance of
neuropathic pain. Pain Pract 2010; 10: 167–184.
61. Sfikakis PP. The first decade of biologic TNF antagonists
in clinical practice: lessons learned, unresolved issues
and future directions. Curr Dir Autoimmun 2010; 11:
180–210.
62. Korhonen T, Karppinen J, Paimela L, et al. The treatment
of disc herniation-induced sciatica with infliximab: results
of a randomized, controlled, 3-month follow-up study.
Spine (Phila Pa 1976) 2005; 30: 2724–2728.
63. Tobinick E and Davoodifar S. Efficacy of etanercept deliv-
ered by perispinal administration for chronic back and/or
neck disc-related pain: a study of clinical observations in
143 patients. Curr Med Res Opin 2004; 20: 1075–1085.
64. Watanabe K, Yabuki S, Sekiguchi M, et al. Etanercept
attenuates pain-related behavior following compression
of the dorsal root ganglion in the rat. Eur Spine J 2011;
20: 1877–1884.
12 Molecular Pain 0(0)
